State of New Jersey Common Pension Fund D Acquires New Stake in Apellis Pharmaceuticals, Inc. $APLS

State of New Jersey Common Pension Fund D purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 25,863 shares of the company’s stock, valued at approximately $650,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp grew its position in shares of Apellis Pharmaceuticals by 206.8% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after buying an additional 1,373 shares during the last quarter. Osaic Holdings Inc. lifted its stake in shares of Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after purchasing an additional 1,570 shares during the period. Allworth Financial LP lifted its stake in shares of Apellis Pharmaceuticals by 64.1% in the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after purchasing an additional 857 shares during the period. Quantbot Technologies LP acquired a new position in Apellis Pharmaceuticals during the third quarter worth $64,000. Finally, EverSource Wealth Advisors LLC raised its position in Apellis Pharmaceuticals by 338.5% during the second quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after acquiring an additional 4,191 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

Shares of APLS opened at $41.02 on Tuesday. The firm has a market cap of $5.25 billion, a price-to-earnings ratio of 40.22 and a beta of -0.24. The company has a quick ratio of 3.16, a current ratio of 3.63 and a debt-to-equity ratio of 0.87. The business’s 50 day moving average is $31.12 and its two-hundred day moving average is $25.78. Apellis Pharmaceuticals, Inc. has a 52-week low of $16.10 and a 52-week high of $41.14.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.44. The firm had revenue of $268.30 million for the quarter, compared to the consensus estimate of $208.91 million. Apellis Pharmaceuticals had a net margin of 12.06% and a return on equity of 39.71%. Analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Roth Mkm lowered Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Mizuho increased their price objective on shares of Apellis Pharmaceuticals from $20.00 to $41.00 and gave the stock a “neutral” rating in a report on Thursday, April 2nd. Needham & Company LLC lowered Apellis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Weiss Ratings raised shares of Apellis Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $41.00 target price (up from $37.00) on shares of Apellis Pharmaceuticals in a research report on Wednesday, April 1st. Three equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $35.72.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.